A Phase I/II Study of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Sep 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2018 Status changed from not yet recruiting to recruiting.
- 15 Jan 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.